Skip to search formSkip to main contentSkip to account menu

tesaglitazar

Known as: (2S)-2-Ethoxy-3-(4-(2-(4-((methylsulfonyl)oxy)phenyl)ethoxy)phenyl)propanoic acid, 2-ethoxy-3-(4-((4-(methylsulfonyloxy)phenethyl)oxy)phenyl)propanoic acid, (S)-2-ethoxy-3-(4-(2-(4-methylsulphonyloxyphenyl)ethoxy)phenyl)propanoic acid 
A dual peroxisome proliferator-activated receptor (PPAR) agonist, with hypoglycemic activity. Tesaglitazar is more potent on the gamma subtype than… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

AZ 242

Broader (2)

AlkanesulfonatesPhenylpropionates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Tesaglitazar, is predominantly metabolized (to an acyl glucuronide of the parent… 
Highly Cited
2007
Highly Cited
2007
Peroxisome Proliferator–Activated Receptor α/γ Dual Agonist Tesaglitazar Attenuates Diabetic Nephropathy in db/db Mice
Peroxisome proliferator–activated receptors (PPARs) are nuclear transcription factors and play a central role in insulin… 
2007
2007
Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes
This randomised, double-blind, parallel-group, mul-ticentre study investigated the effects of the dual peroxisome proliferator… 
2007
2007
Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.
The development of the dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist tesaglitazar as an oral… 
2007
2007
The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes
This study assessed the effects of tesaglitazar (0.5 or 1 mg/day), a dual peroxisome proliferator-activated receptor α/γ agonist… 
2007
2007
Learning from tesaglitazar
161 The development of glucose intolerance and type 2 diabetes is typically associated with multiple disturbances of endocrine… 
2006
2006
Dual PPAR&agr;/&ggr; Agonist Tesaglitazar Reduces Atherosclerosis in Insulin-Resistant and Hypercholesterolemic ApoE*3Leiden Mice
Objective—We investigated whether the dual PPAR&agr;/&ggr; agonist tesaglitazar has anti-atherogenic effects in ApoE*3Leiden mice… 
Review
2006
Review
2006
Tesaglitazar: a promising approach in type 2 diabetes.
While glycemic control remains the cornerstone of clinical management for patients with type 2 diabetes, the importance of a more… 
2005
2005
Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.
Insulin resistance, impaired glucose tolerance, high circulating levels of free fatty acids (FFA), and postprandial… 
2004
2004
Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar.
Agonists of peroxisome proliferator-activated receptors (PPARs) have emerged as important pharmacological agents for improving… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)